Xylazine (Tranq): The Emerging Drug Crisis

What Is Xylazine?

Xylazine is a powerful sedative and muscle relaxant used in veterinary medicine to sedate large animals. It is an alpha-2 adrenergic agonist. The FDA has approved xylazine solely for veterinary use — it has never been approved for use in humans.

Xylazine has infiltrated the illegal drug supply across the United States at an alarming pace. It is commonly added to fentanyl and sometimes to heroin, cocaine, and methamphetamine to extend or intensify effects or increase street value. The resulting mixtures are called "tranq" or "tranq dope." Most people who consume xylazine do so unknowingly.

In April 2023, the White House designated fentanyl combined with xylazine as an "emerging drug threat." The DEA reported that approximately 23% of fentanyl powder and 7% of fentanyl pills seized in 2022 contained xylazine, and mixtures have been found in 48 of 50 states.

Why Is Xylazine So Dangerous?

• Naloxone does not reverse xylazine's effects. Because xylazine is not an opioid, Narcan has no effect on it. However, since fentanyl is almost always present alongside xylazine, naloxone should still be administered in any suspected overdose.
• Severe respiratory depression occurs because xylazine depresses the central nervous system, and when combined with fentanyl, the compounded effect creates extremely high risk of fatal respiratory failure.
• Prolonged sedation can last hours, leading to the street name "zombie drug." During these periods, individuals are vulnerable to environmental exposure, assault, theft, and positional injuries.
• Devastating skin wounds ("tranq wounds") are deep, slow-healing, necrotic ulcers that can appear at injection sites — but research shows they can develop even in people who snort or smoke xylazine-contaminated drugs.
• Complicated withdrawal from xylazine combined with opioids may include symptoms distinct from opioid withdrawal alone, including severe anxiety, agitation, and worsening of skin wounds.

Signs of Xylazine Exposure

• Extreme, prolonged drowsiness far longer than typical opioid use
• Slurred speech or inability to be roused
• Unusually slow breathing, heart rate, and blood pressure
• Open, slow-healing skin wounds or ulcers on arms and legs
• Wounds that worsen or don't respond to first aid
• Skin infections, abscesses, or necrotic tissue

Treatment for Xylazine-Related Addiction

Medical detox with enhanced monitoring is recommended because combined opioid-xylazine withdrawal can be more severe and unpredictable. Standard MOUD medications (methadone, buprenorphine, naltrexone) address the opioid component — there is currently no FDA-approved medication specifically for xylazine dependence.

• Wound care is critical for tranq wounds
• Behavioral therapy (CBT, MI, group) addresses underlying addiction
• Harm reduction services (naloxone, fentanyl test strips, wound care outreach, syringe service programs, never-use-alone services) can save lives for those not yet in formal treatment

Related Resources